CAR-T Hematology Deal Benchmarks

Median Upfront

$247M

Range: $99M - $412M

Total Deal Value

$2.1B

Range: $1.0B - $3.1B

Royalty Rate

5.7% - 12.6%

Tiered up to 16.6%

Dev Milestones

$615M

Range: $316M - $908M

Model Your Deal

Market Analysis

CAR-T cell therapy in hematologic malignancies remains the most clinically validated application of engineered cell therapy, with six approved products generating $5B+ in combined annual revenue. Phase 1 CAR-T hematology deals carry a median total deal value of $2.1B, with upfront payments of $247M. The validated clinical paradigm and established manufacturing infrastructure support deal premiums even at early clinical stages.

Milestone structures in hematology CAR-T deals reflect the established clinical pathway. Development milestones average $615M, with key gates at Phase 1 dose selection, pivotal trial initiation, and BLA filing. Regulatory milestones of $506M and commercial milestones of $687M reward successful market entry and indication expansion.

Royalty rates for hematology CAR-T deals range from 5.7% to 12.6%, reflecting the unique manufacturing economics of autologous cell therapy. Allogeneic and in-vivo CAR-T approaches that address scalability limitations can command higher total deal values. Next-generation targets beyond CD19 and BCMA (GPRC5D, CD70, CD22) are driving the next wave of licensing activity.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for hematology CAR-T licensing?

Phase 1 hematology CAR-T deals average $247M upfront with $2.1B total deal value. The 12/88 upfront/milestone split is standard for early-stage cell therapy assets.

How do autologous vs. allogeneic CAR-T deal terms differ?

Autologous CAR-T deals benefit from clinical validation but face scalability constraints. Allogeneic (off-the-shelf) CAR-T platforms can command 15-25% higher total deal values due to broader commercial scalability, despite earlier clinical development. In-vivo CAR-T approaches represent the next frontier with potentially transformative manufacturing economics.

Which CAR-T targets are most actively licensed in hematology?

CD19 (lymphoma, ALL) and BCMA (myeloma) remain the most validated targets with approved products. Emerging targets include GPRC5D (myeloma), FcRH5 (myeloma), CD70 (AML), and CD22 (ALL). Dual-target constructs (CD19/CD22, BCMA/GPRC5D) are attracting premium deal terms.

What manufacturing factors affect CAR-T deal valuations?

Manufacturing platform maturity significantly impacts deal terms. Established GMP manufacturing with short vein-to-vein time commands premium valuations. Novel manufacturing approaches (point-of-care, automated systems) can increase total deal values by 10-20% due to improved commercial scalability.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

CAR-T Hematology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Hematology Deal Overview

Bispecific Hematology Deals

CAR-T Deals (Oncology)

Gene Therapy Deals

Ready to Calculate Your Deal Terms?